Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31201635 | 0.85 | NPC1 (0.47) | LMNANPC1RAB9AMAPK1L3MBTL1 | |
| SCHEMBL19581035 | 0.84 | LMNA (0.48) | LMNANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL12970762 | 0.84 | PARP10 (0.41) | KMT2AALDH1A1 | |
| SCHEMBL224261 | 0.84 | LMNA (0.41) | LMNANPC1RAB9AKMT2AADRB2 | |
| SCHEMBL1712501 | 0.83 | NPC1 (0.45) | LMNANPC1RAB9APTPN1PLOD2 | |
| SCHEMBL30968940 | 0.83 | CES2 (0.43) | RAB9AKMT2AALDH1A1 | |
| SCHEMBL15512384 | 0.82 | CES2 (0.45) | LMNANPC1RAB9AKMT2AKDM4E | |
| SCHEMBL15496340 | 0.81 | ALDH1A1 (0.49) | NPC1RAB9AL3MBTL1KMT2AKDM4E | |
| SCHEMBL15229021 | 0.81 | SMN1; SMN2 (0.41) | NPC1MAPK1CASP3SENP7KMT2A | |
| SCHEMBL25081054 | 0.80 | GSR (0.47) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-2465847-B1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2016-10-12 | — | — | EP | disclosed |
| US-8623855-B2 | Azetidinone compounds and medical use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-01-07 | — | — | US | disclosed |
| US-8623855-B2 | Azetidinone compounds and medical use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-01-07 | — | — | US | disclosed |
| US-8580956-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120208994-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2012-08-16 | — | — | US | disclosed |
| US-20120208994-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2012-08-16 | — | — | US | disclosed |
| EP-2465847-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2012-06-20 | — | — | EP | disclosed |
| US-20100255005-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-10-07 | — | — | US | disclosed |
| EP-2164852-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008153792-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100255005-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 676/4885NPC1 578/4885RAB9A 1415/4885 |
| US-20120208994-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | CYP46A1, APOB, CETP | LMNA 1008/4885NPC1 12/4885RAB9A 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.